Ophthalmologists Report Significant Changes In Prescribing Among Primary Open Angle Glaucoma Patients As Pfizer’s Xalatan Goes Generic

The impact of the genericization of Pfizer's Xalatan at the end of March 2011 is reflected in changes to both current and anticipated ophthalmologist prescribing behavior for primary open angle glaucoma (POAG) patients.

Full Story →